Table 6. Adverse events reported by the patients or spotted by the study investigators.

	Visit 1 (3 months from the baseline) (n=1249)	Visit 2 (6 months from the baseline) (n=1229)	Visit 3 (9 months from the baseline) (n=1194)
No adverse events (No, %)	1219 (97.6%)	1215 (98.9%)	1191 (99.7%)
Cough (No, %)	13 (1.0%)	3 (0.2%)	3 (0.3%)
Headache (No, %)	9 (0.7%)	3 (0.2%)	—
Vertigo (No, %)	3 (0.2%)	1 (0.1%)	—
Increase in blood pressure (No, %)	2 (0.2%)	—	—
Nausea (No, %)	1 (0.1%)	1 (0.1%)	—
Fainting (No, %)	—	2 (0.2%)	—
Hair loss (No, %)	1 (0.1%)	—	—
Tinitus (No, %)	—	1 (0.1%)	—
Rash (No, %)	1 (0.1%)	—	—
Dyspepsia (No, %)	—	1 (0.1%)	—
Hypotension (No, %)	—	1 (0.1%)	—
Weight loss (No, %)	—	1 (0.1%)	—